The clinical significance of uric acid and complement activation in the progression of IgA nephropathy

Kidney and Blood Pressure Research

Volumn 41, Issue 2, 2016, Pages 148-157

  Caliskan, Yasar ^a   Ozluk, Yasemin ^b   Celik, Dilara ^a   Oztop, Nida ^b   Aksoy, Aysun ^b   Ucar, Ayse Serra ^a   Yazici, Halil ^a   Kilicaslan, Isin ^b   Sever, Mehmet Sukru ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Biomarkers; Complement; End stage renal disease; IgA Nephropathy; Uric acid

Indexed keywords

ALBUMIN; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; CREATININE; HEMOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; URIC ACID; BIOLOGICAL MARKER;

ADULT; AGE DISTRIBUTION; ALBUMIN BLOOD LEVEL; ARTICLE; COMPLEMENT ACTIVATION; CREATININE BLOOD LEVEL; DISEASE COURSE; FEMALE; FOLLOW UP; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HYPERURICEMIA; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; OUTCOME VARIABLE; PRIORITY JOURNAL; PROTEINURIA; RISK FACTOR; SEX DIFFERENCE; URIC ACID BLOOD LEVEL; ADOLESCENT; AGED; BLOOD; DISEASE EXACERBATION; MIDDLE AGED; PHYSIOLOGY; RETROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS; COMPLEMENT ACTIVATION; COMPLEMENT C3; DISEASE PROGRESSION; FEMALE; GLOMERULONEPHRITIS, IGA; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; URIC ACID; YOUNG ADULT;

EID: 84963849976     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000443415     Document Type: Article

References (38)

1. Schena FP, Montenegro M, Scivittaro V. Meta-Analysis of randomised controlled trials in patients with primary IgA nephropathy (Berger's disease). Nephrol Dial Transplant 1990; 5: S47-52
2. Tomino Y. Pathogenesis and treatment of chronic kidney disease: a review of our recent basic and clinical data. Kidney Blood Press Res 2014; 39: 450-489
3. Kiryluk K, Li Y, Sanna-Cherchi S, Rohanizadegan M, Suzuki H, Eitner F, Snyder HJ, Choi M, Hou P, Scolari F, Izzi C, Gigante M, Gesualdo L, Savoldi S, Amoroso A, Cusi D, Zamboli P, Julian BA, Novak J, Wyatt RJ, Mucha K, Perola M, Kristiansson K, Viktorin A, Magnusson PK, Thorleifsson G, Thorsteinsdottir U, Stefansson K, Boland A, Metzger M, Thibaudin L, Wanner C, Jager KJ, Goto S, Maixnerova D, Karnib HH, Nagy J, Panzer U, Xie J, Chen N, Tesar V, Narita I, Berthoux F, Floege J, Stengel B, Zhang H, Lifton RP, Gharavi AG. Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet 2012; 8: e1002765
4. Caliskan Y, Kiryluk K. Novel Biomarkers in Glomerular Disease. Adv Chronic Kidney Dis 2014; 21: 205-216
5. Tan M, Li W, Zou G, Zhang C, Fang J. Clinicopathological features and outcomes of IgA nephropathy with hematuria and/or minimal proteinuria. Kidney Blood Press Res 2015; 40: 200-206
6. Goto M, Wakai K, Kawamura T, Ando M, Endoh M, Tomino Y. A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. Nephrol Dial Transplant 2009; 24: 3068-3074
7. Maixnerova D, Neprasova M, Skibova J, Mokrisova J, Rysava R, Reiterova J, Jancova E, Merta M, Zadrazil J, Honsova E, Tesar V. IgA nephropathy in Czech patients-Are we able reliably predict the outcome? Kidney Blood Press Res 2014; 39: 555-562
8. Kim SJ, Koo HM, Lim BJ, Oh HJ, Yoo DE, Shin DH, Lee MJ, Doh FM, Park JT, Yoo TH, Kang SW, Choi KH, Jeong HJ, Han SH. Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy. PLoS One 2012; 7: e40495
9. Nakagawa H, Suzuki S, Haneda M, Gejyo F, Kikkawa R. Significance of glomerular deposition of C3c and C3d in IgA nephropathy. Am J Nephrol 2000; 20: 122-128
10. Ohno I, Hosoya T, Gomi H, Ichida K, Okabe H, Hikita M. Serum uric acid and renal prognosis in patients with IgA nephropathy. Nephron 2001; 87: 333-339
11. Myllymaki J, Honkanen T, Syrjanen J, Helin HJ, Rantala IS, Pasternack AI, Mustonen JT. Uric acid correlates with the severity of histopathological parameters in IgA nephropathy. Nephrol Dial Transplant 2005; 20: 89-95
12. Zwirner J, Burg M, Schulze M, Brunkhorst R, Götze O, Koch KM, Floege J. Activated complement C3: a potentially novel predictor of progressive IgA nephropathy. Kidney Int 1997; 51: 1257-1264
13. Endo M, Ohi H, Ohsawa I, Fujita T, Matsushita M. Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. Nephrol Dial Transplant 1998; 13: 1984-1990
14. Hiemstra PS, Gorter A, Stuurman ME, Van Es LA, Daha MR. Activation of the alternative pathway of complement by human serum IgA. Eur J Immunol 1987; 17: 321-326
15. Roos A, Bouwman LH, Van Gijlswijk-Janssen DJ, Faber-Krol MC, Stahl GL, Daha MR. Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol 2001; 167: 2861-2868
16. Maillard N, Wyatt RJ, Julian BA, Kiryluk K, Gharavi A, Fremeaux-Bacchi V, Novak J. Current Understanding of the Role of Complement in IgA Nephropathy. J Am Soc Nephrol 2015; 26: 1503-1512
17. Zhu L, Zhai YL, Wang FM, Hou P, Lv JC, Xu DM, Shi SF, Liu LJ, Yu F, Zhao MH, Novak J, Gharavi AG, Zhang H. Variants in Complement Factor H and Complement Factor H-Related Protein Genes, CFHR3 and CFHR1, Affect Complement Activation in IgA Nephropathy. J Am Soc Nephrol 2015; 26: 1195-1204
18. Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, Cattran DC, Coppo R, D'Agati V, D'Amico G, Emancipator S, Emma F, Feehally J, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009; 76: 546-556
19. Coppo R, Troyanov S, Bellur S, Cattran D, Cook HT, Feehally J, Roberts IS, Morando L, Camilla R, Tesar V, Lunberg S, Gesualdo L, Emma F, Rollino C, Amore A, Praga M, Feriozzi S, Segoloni G, Pani A, Cancarini G, Durlik M, Moggia E, Mazzucco G, Giannakakis C, Honsova E, Sundelin BB, Di Palma AM, Ferrario F, Gutierrez E, Asunis AM, Barratt J, Tardanico R, Perkowska-Ptasinska A; VALIGA study of the ERA-EDTA Immunonephrology Working Group: Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int 2014; 86: 828-836
20. KDIGO: Summary of Recommendation Statements. Kidney Int Suppl. (2011). 2013; 3: 5-14
21. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612
22. Bakan A, Oral A, Elcioglu OC, Takir M, Kostek O, Ozkok A, Basci S, Sumnu A, Ozturk S, Sipahioglu M, Turkmen A, Voroneanu L, Covic A, Kanbay M. Hyperuricemia is associated with progression of IgA nephropathy. Int Urol Nephrol 2015; 7: 673-678
23. Zhou J, Chen Y, Liu Y, Shi S, Li X, Wang S, Zhang H. Plasma uric acid level indicates tubular interstitial lesions at early stage of IgA nephropathy. BMC Nephrol 2014; 15: 11
24. Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y. Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. Hypertension 2006; 47: 195-202
25. Uedono H, Tsuda A, Ishimura E, Yasumoto M, Ichii M, Ochi A, Ohno Y, Nakatani S, Mori K, Uchida J, Nakatani T, Inaba M. Relationship between serum uric acid levels and intrarenal hemodynamic parameters. Kidney Blood Press Res 2015; 40: 315-322
26. Yelken B, Caliskan Y, Gorgulu N, Altun I, Yilmaz A, Yazici H, Oflaz H, Yildiz A. Reduction of uric acid levels with allopurinol treatment improves endothelial function in patients with chronic kidney disease. Clin Nephrol 2012; 77: 275-282
27. Rodenbach KE, Schneider MF, Furth SL, Moxey-Mims MM, Mitsnefes MM, Weaver DJ, Warady BA, Schwartz GJ. Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study. Am J Kidney Dis 2015; 66: 984-992
28. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, Johnson RJ. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002; 282: 991-997
29. Kang DH, Han L, Ouyang X, Kanellis J, Li P, Feng L, Nakagawa T, Watanabe S, Hosoyamada M, Endou H, Lipkowitz M, Abramson R, Mu W, Johnson RJ. Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol 2005; 25: 425-433
30. Tomino Y. IgA nephropathy: lessons from an animal model, the ddY mouse. J Nephrol 2008; 21: 463-467
31. Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CN, Knott SA, Kolcic I, Polasek O, Graessler J, Wilson JF, Marinaki A, Riches PL, Shu X, Janicijevic B, Smolej-Narancic N, Gorgoni B, Morgan J, Campbell S, Biloglav Z, Barac-Lauc L, Pericic M, Klaric IM, Zgaga L, Skaric-Juric T, Wild SH, Richardson WA, Hohenstein P, Kimber CH, Tenesa A, Donnelly LA, Fairbanks LD, Aringer M, McKeigue PM, Ralston SH, Morris AD, Rudan P, Hastie ND, Campbell H, Wright AF. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008; 40: 437-442
32. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, Matsuo H, Kikuchi Y, Oda T, Ichida K, Hosoya T, Shimokata K, Niwa T, Kanai Y, Endou H. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417: 447-452
33. Rauterberg EW, Lieberknecht HM, Wingen AM, Ritz E. Complement membrane attack (MAC) in idiopathic IgA-glomerulonephritis. Kidney Int 1987; 31: 820-829
34. Stangou M, Alexopoulos E, Pantzaki A, Leonstini M, Memmos D. C5b-9 glomerular deposition and tubular alpha3 beta1-integrin expression are implicated in the development of chronic lesions and predict renal function outcome in immunoglobulin A nephropathy. Scand J Urol Nephrol 2008; 42: 373-380
35. Roos A, Rastaldi MP, Calvaresi N, Oortwijn BD, Schlagwein N, Van Gijlswijk-Janssen DJ, Stahl GL, Matsushita M, Fujita T, Van Kooten C, Daha MR. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 2006; 17: 1724-1734
36. Bartosik LP, Lajoie G, Sugar L, Cattran DC. Predicting progression in IgA nephropathy. Am J Kidney Dis 2001; 38: 728-735
37. Donadio JV, Bergstralh EJ, Grande JP, Rademcher DM. Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. Nephrol Dial Transplant 2002; 17: 1197-1203
38. Choi S, Lee D, Jeong KH, Moon JY, Lee SH, Lee TW, Ihm CG. Prognostic relevance of clinical and histological features in IgA nephropathy treated with steroid and angiotensin receptor blockers. Clin Nephrol 2009; 72: 353-359